Feedback
We’d love to hear your feedback on this activity. It helps us to continually improve our products.
CORRECT!
Faculty & Disclosures
Prof. Enriqueta Felip
Vall d’Hebron University Hospital, Barcelona, Spain
Prof. Enriqueta Felip is a medical oncologist and section chief at the Vall d’Hebron University Hospital (HUVH) in Barcelona, Spain. She is also head of the Vall d’ Hebron Institute of Oncology’s (VHIO) Thoracic Tumors Group. Since March 2024, Prof. Felip has been a full professor of medicine at the Autonomous University of Barcelona. read more
Prof. Felip’s research focuses on accelerating more effective personalized and targeted cancer medicines matched to specific molecular alterations, unmasking molecular mechanisms of acquired cancer drug resistance and optimizing immune-based strategies in both advanced and early-stage NSCLC.
Prof. Felip is a member of the scientific committees of the Spanish Lung Cancer Group (SLCG) and the European Thoracic Oncology Platform (ETOP). She served as president of the Spanish Society of Medical Oncology (SEOM) from 2021 to 2023 and was elected as a member of the Board of Directors of the International Association for the Study of Lung Cancer (IASLC) from 2017 to 2021. Prof. Felip has also been a member of the educational and scientific committees of the European Society for Medical Oncology (ESMO), World Conference on Lung Cancer (WCLC) and European Lung Cancer Conference (ELCC).
Prof. Felip was subject editor of the Guidelines Working Group for the ESMO Minimum Clinical Recommendations in lung cancer (2006–2014) and coordinator of the first ESMO Consensus Conference on Lung Cancer. In 2015, she received the first ESMO Women for Oncology Award. Prof. Felip was co-chair of the IASLC 20th WCLC in 2019.Â
Prof. Felip serves on the editorial boards of various top-tier journals including Annals of Oncology and the Journal of Thoracic Oncology. She has authored or co-authored approximately 400 peer-reviewed papers.
Prof. Enriqueta Felip discloses: Advisory board or panel fees from Abbvie, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, F. Hoffmann-La Roche, Genmab, Gilead, GSK, Janssen, Johnson & Johnson, Merck Serono, Merck Sharp & Dohme, Novartis, Peptomyc, Pfizer, Regeneron and Sanofi. Other financial or material support from AstraZeneca, Janssen and Roche. Speaker’s bureau fees from Amgen, AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Eli Lilly, F. Hoffmann-La Roche, Janssen, Merck Serono, Merck Sharp & Dohme, Pfizer, Regeneron, Sanofi, Seagen and Takeda.
Prof. Keith Kerr
Aberdeen Royal Infirmary,
Aberdeen, UK
Prof. Keith Kerr is a consultant pathologist for NHS Grampian and honorary chair in pulmonary pathology at the University of Aberdeen in Scotland. read more
Prof. Kerr is the past chair of the International Association for the Study of Lung Cancer (IASLC) Pathology Committee and served on the IASLC Board of Directors from 2013 to 2017. He received the IASLC Mary Matthews Pathology/Translational Research Award in 2016 and the Lifetime Achievement Award from the British Thoracic Oncology Group in 2019.Â
Prof. Kerr is a member of the European Society for Medical Oncology (ESMO) lung/thoracic educational faculty and the European Thoracic Oncology Platform Translational Research Group, and has served on the panel (author/editor) for the 2004, 2015 and 2021 World Health Organization lung cancer classifications. He is co-author of many international guidelines concerning the diagnosis and management of lung cancer and mesothelioma, including the IASLC and ESMO guidelines. He has worked on numerous lung cancer trial groups and conference scientific committees, and is an associate editor for the Journal of Thoracic Oncology.
Prof. Keith Kerr discloses: Advisory board or panel fees from AbbVie, Amgen, AstraZeneca, Bayer, Bristol Myers Squibb, Daiichi Sankyo, Janssen, Merck Serono, Merck Sharp & Dohme, Novartis, Pfizer, Regeneron, Roche, Sanofi, Takeda and Ventana (all relationships terminated). Speaker’s bureau fees from AstraZeneca, Amgen, Bristol Myers Squibb, Janssen, Merck Serono, Merck Sharp & Dohme, Novartis, Pfizer, Roche, Sanofi and Ventana (all relationships terminated).
